Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Seagen

Pfizer (PFE) continues to make significant strides in the pharmaceutical industry, given its recent acquisition and drug approvals. Is the stock a buy, sell, or hold now? Keep reading to find out….

StockNews.com

Horizon Tumbles — Taking Seagen, Prometheus With It — As FTC Blocks Amgen Takeover

The FTC plans to block Amgen's takeover of Horizon. The move reverberated across biotechs, with an HZNP stock crash leading the way.

Investors Business Daily

Adding These 2 Stocks to Your Portfolio Could End up Being a Genius Move

Due to still-high inflation and the Fed’s rate hikes, stock market volatility is anticipated to persist. However, fundamentally sound stocks Pfizer (PFE) and Honda Motor (HMC) could be a solid addition to your portfolio. Let's discuss.

StockNews.com

From analysis to the latest developments in health,
read the most diverse news in one place.

4 Robinhood Stocks to Buy Right Now

Zero-commission trading platform Robinhood is highly attractive to Gen Z and millennial investors. Therefore, stocks traded on the Robinhood platform are considered popular and trending. While all Robinhood stocks are not fundamentally sound, Taiwan Semiconductor Manufacturing (TSM), Pfizer (PFE), General Motors (GM), and Nokia (NOK) hold the potential to deliver…

StockNews.com

3 Best Stocks to Buy and Hold for a Lifetime

With inflation still alarmingly high, the Fed is poised to raise interest rates further. This is predicted to keep the stock market volatile. Amid this, investors should focus on their long-term strategies and buy fundamentally strong stocks Visa (V), Pfizer (PFE), and Molina Healthcare (MOH), which have solid growth potential.…

StockNews.com

Pfizer to pay $43 billion for Seagen, set post-COVID course

Pfizer Inc. is purchasing cancer-drug maker Seagen Inc. for an enterprise value of $43 billion, using the biggest deal of the year to set its course out of the pandemic and back into mainstream pharma.

Tribune News Service

Pfizer to buy cancer drugmaker Seagen in $43 billion deal

Pfizer Inc. agreed to purchase cancer-drug maker Seagen Inc. for an enterprise value of $43 billion, gaining the company’s antibody drugs that fight tumors.

Tribune News Service

Read news from The Economist, FT, and more,
with one subscription

Pfizer buys biotech firm Seagen for $43 billion

WASHINGTON - US pharmaceutical giant Pfizer announced Monday that it had reached a deal to buy biotech firm Seagen, specializing in innovative cancer treatment, for $43 billion.

Bangkok Post

Seagen Nabs $43 Billion Pfizer Deal; Sanofi Scoops Up Provention Bio

Pfizer will buy Seagen for roughly $43 billion, and Sanofi will buy Provention for $2.9 billion. SGEN stock and PRVB stock soared.

Investors Business Daily

Dow Jones Reverses On SVB Rescue Plan; First Republic, Charles Schwab Crash On Bank Fears

The Dow Jones fell Monday, as the FDIC guaranteed all deposits of SVB Financial. First Republic crashed 75% on ongoing bank fears.

Investors Business Daily

Pfizer will spend $43 billion to acquire Seagen

Pfizer will spend about $43 billion to buy Seagen and broaden its reach into cancer treatments, the pharmaceutical giant said Monday

The Independent UK

Hot Stocks And Hot Wings Serve Up Spicy Breakouts And Buy Zones

As the market indexes fight for support, ANET, WING, BKNG, CDNS, PANW and more land a spot on the IBD Breakout Stocks Index.

Investors Business Daily

'Here We Go Again': Seagen Soars As Pfizer Reportedly Mulls A Takeover

Pfizer is in early talks to acquire cancer specialist Seagen, according to a report that sent SGEN stock flying on Monday.

Investors Business Daily

Biogen, Seagen Name New CEOs — But One Biotech Stock Crumbles

Biogen and Seagen tapped new CEOs on Thursday but the biotech stocks diverged following the long-anticipated announcements.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Provention Bio's Second Try, Apellis's Eye Disorder Drug Review, 3 Adcom Verdicts And More: November's Key PDUFA Catalysts Biotech Investors Must Know

Editor's note: This story has been corrected to reflect that the FDA deferred action on Amicus Therapeutics' Biologics License Application.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For October 11, 2022

Upgrades

Investors Business Daily

Something Unusual Is Happening Right Now With Biotech Stocks

Biotech stocks have swung sharply higher, buoyed by several factors. Could they be poised to lead the market though the next big upturn?

Investors Business Daily

Merck Gambled With Keytruda In 2011 — How That Jump Is Still Paying Off Today

A gamble could pay off for Merck stock after blockbuster Keytruda nearly doubled the five-year survival rate for some lung cancer patients.

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Merck's Rumored $40 Billion Seagen Takeover Hits A Snag On Price

Merck's rumored takeover of cancer-focused biotech Seagen has stalled on price, according to a report Friday that sent SGEN stock tumbling.

Benzinga

Benzinga Before The Bell: Elon Musk's Demand For Broad Twitter Data Dismissed, Xiaomi Wants To Join EV Race, Bed Bath & Beyond Plans To Share Turnaround Strategy Next Week And Other Top Financial Stories Friday, August 26

CNBC The Aviation Sector Is Slammed By Sky-High Rents

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For August 16, 2022

Investors Business Daily

Does Merck Finally Have The Fodder It Needs To Buy Seagen?

Seagen lost a royalty battle Friday, but SGEN stock jumped on the potential the rumored Merck acquisition could be looming.

Benzinga

Recap Of Tuesday's Biotech Catalysts - End of The Day Summary

European Commission (EC) has approved AbbVie’s (NYSE:ABBV) lead asset RINVOQ (upadacitinib 45 mg [induction dose] and 15 mg and 30 mg [maintenance doses]) for the treatment of adult patients with moderately to severely active ulcerative colitis. AbbVie shares traded in a range of $150.33 to $153.56 on a day volume…

Investors Business Daily

Seagen Tips Its Hand In Bladder Cancer, But Is It Enough To Woo Merck?

Nearly two-thirds of bladder cancer patients responded to a combination from Seagen and Merck, leading SGEN stock to jump Tuesday.

Investors Business Daily

IBD Stock Of The Day XBI: How To Trade Blazing-Hot Biotech Stocks Without Getting Burned

The SPDR S&P Biotech ETF is the IBD Stock Of The Day. XBI stock has shucked off near-term resistance on enthusiasm for biotech stocks.

1 2 3 4

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Amyotrophic lateral sclerosis

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.